598345 Disclosed is the use of an anti-GM-CSF antibody for preparing a medicament for reducing the symptoms of rheumatoid arthritis in a patient undergoing treatment with methotrexate without inducing clinically significant neutropenia in which the absolute neutrophil count is less than 0.5 x 109/l, wherein the anti-GM-CSF antibody is a GM-CSF antagonist, and further, wherein the methotrexate is provided to the patient in an amount of 7.5 mg to 25 mg/week and the anti-GMCSF antibody is provided in an amount of 0.1 to 25 mg/week. Further disclosed is the use of an anti-GM-CSF antibody for preparing a medicament for reducing the symptoms of rheumatoid arthritis in a patient undergoing treatment with methotrexate without inducing clinically significant neutropenia in which the absolute neutrophil count is less than 0.5 x 109/l, wherein the anti-GM-CSF antibody is an antagonist and the medicament is formulated for administering the anti-GM-CSF antibody to the patient in an amount of 0.1 to 25 mg/week and the methotrexate is provided in an amount of 0.1 to 25 mg/week.
